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Abstract
Background: Acute bacterial meningitis is still a life threatening disease.
Methods: We performed a retrospective observational study on the clinical characteristics of consecutively
admitted patients with acute pneumococcal meningitis in a single tertiary care center in central Europe
(from 2003 until 2015). Data were compared with a previously published historical group of 87 patients
treated for pneumococcal meningitis at the same hospital (from 1984 until 2002).
Results: Fifty-five consecutive patients with microbiologically proven pneumococcal meningitis were included. Most
striking, mortality was down to 5.5 %, which was significantly lower than in the historical group where 24.1 % of the
patients did not survive. Intracranial complications during the course of the disease were common and affected half
of the patients. Unlike in the historic group, most of the intracranial complications (except ischemic stroke) were no
longer associated with a low Glasgow Outcome Score at discharge.
Conclusion: The drastic reduction of mortality proves there have been important advances in the treatment of
pneumococcal meningitis. Nevertheless, the fact that only 44.2 % of survivors had a full recovery indicates that the
search for new adjunctive treatment options must be ongoing.
Keywords: Bacterial meningitis, Pneumococcal meningitis, Neurocritical care, CNS infection, Streptococcus
pneumoniae, Intracranial complications
Background
Streptococcus pneumoniae is not only the most frequent
but also one of the most threatening pathogens causing
acute bacterial meningitis. Fatality rates are still high,
and up to 17 % of patients die [1, 2]. Patients surviving
pneumococcal meningitis often suffer from long-term
neurological sequelae such as impaired neuropsycho-
logical abilities or focal neurological deficits ranging from
cranial nerve palsy to hemiparesis [3–5]. Frequently, those
sequelae are consequences of intracranial complications
occurring during the course of the disease, such as intra-
cranial hemorrhage, brain edema, cerebritis, empyema,
sinus thrombosis, cerebral ischemia and others. Moreover,
potentially fatal systemic complications such as septic
shock, intravasal coagulation, acute respiratory distress
syndrome and others occur frequently [6].
In a previous study from our center, 87 cases of pa-
tients suffering from pneumococcal meningitis from
1984 until 2002 were analyzed. The reported in-hospital
mortality rate in that study period was 24 %. Among the
patients, 75 % suffered from intracranial complications
with brain edema being the most frequent (29 %),
followed by hydrocephalus (16 %), arterial complications
(22 %) and venous cerebrovascular complications (9 %).
Only 48 % of patients had a good clinical outcome
defined by a Glasgow Outcome Scale (GOS) of 5 [3].
We have since reviewed the patients’ records from the
previous study to assess the current characteristics of
medical care and outcome in patients with pneumococ-
cal meningitis, beginning in 2003 and leading up to
today.
Methods
All inpatients suffering from bacterial meningitis and
treated at the Neurological Department of the University
of Munich from 2003 to 2015 were identified. The
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Neurological Department of the University of Munich is
part of a tertiary care hospital (Klinikum Grosshadern)
in Munich, Germany. A neurologist is present at the
emergency department 24 h a day, 7 days a week. This
neurologist is not involved in the patient workup as a
consultant, but sees all patients with a presumed neuro-
logical diagnosis “front line”.
In the case of suspected bacterial meningitis, diagnos-
tic workup and empiric therapy are initiated according
to national guidelines (steroids were introduced after
publication of the Dutch dexamethasone study [7–9]).
All patients received cerebral imaging (usually cerebral
computed tomography (CCT), except when there were
contraindications such as suspected pregnancy), before
admission to the ward to check for (i) intracranial
complications and (ii) infectious foci. The neuro-
logical intensive care unit (NICU) with a capacity for
12 simultaneous patients is run by a team of neurolo-
gists and neuro-intensivists with a focus on the treat-
ment of patients with life-threatening neurological
diseases: more than 95 % of the patients primarily
suffer from a neurologic disease (admission diagnosis).
One main focus of the center is treatment of infec-
tious diseases of the brain [10].
All patients with bacterial meningitis receive stand-
ard neuro-monitoring performed by a skilled nurse
every hour, and this consists of evaluation of con-
sciousness, pupil reaction, speech and limb weakness.
Furthermore, a neurologist evaluates the patient
neurologically four times daily. Follow-up cerebral im-
aging is done immediately in patients with neurologic
deterioration, new-onset focal neurologic deficits or a
persistent loss of consciousness without obvious rea-
sons. Transcranial Doppler sonography is done every
48 h to screen for signs of vasculopathy in the anter-
ior and posterior circulation [11].
In this study, only patients with acute bacterial menin-
gitis in whom S. pneumoniae was detected by microbio-
logical testing were included in the study. This included
patients in whom pneumococci were identified by Gram
staining and microscopy of the cerebrospinal fluid
(CSF), culture from CSF, polymerase chain reaction
(PCR) from CSF, CSF antigen testing or blood culture
(in combination with the following CSF alterations: CSF
pleocytosis, elevated CSF protein, and decreased CSF/
serum glucose ratio <0.3).
Data were obtained from any medical records avail-
able. For assessment of clinical outcome at the time of
discharge from our hospital, we used the GOS (with 1 =
death, 2 = persistent vegetative state, 3 = severe disability,
4 =moderate disability and 5 = good recovery) [12]. A
GOS of 5 was referred to as a “good clinical outcome”.
A GOS of 1–4 was considered as an “unfavorable
outcome”.
As the search for patients and the assessment of
patient data was performed in the same way as in the
previous study by Kastenbauer et al., we compared the
epidemiological and clinical data from our current
patient population with the data from the patients ana-
lyzed from 1984 to 2002 [3]. Figures were prepared and
statistical analysis performed using Graph Pad Prism or
Sigma Plot. All categorical outcomes were determined
using Fisher’s exact test, whereas all continuous
outcomes were compared using the Mann-Whitney test.
Odds ratios (OR) with 95 % confidence intervals (in
Tables 4 and 5) were calculated from 2 × 2 tables. Multi-
variate analysis of risk factors for death or an unfavor-
able outcome (GOS <5) was performed for both study
periods together and for each single study period separ-
ately using multiple logistic regression. The data sup-
porting the conclusions of this article are included
within the article.
Results
From 2003 to 2015, 55 patients suffering from pneumo-
coccal meningitis were treated at our department. Of the
55 patients, 21 were admitted directly from our emer-
gency department and 34 were transferred from another
hospital. Comparing 1984 to 2002, the patients in the re-
cent study were older and more often female (Table 1).
The reported duration of symptoms before admission to
the emergency department was currently lower than
between 1984 and 2002 (p = 0.0047, see Fig. 1). Cerebro-
spinal fistulas were less frequently the underlying entry
route of infection. All other characteristics of the cur-
rently analyzed patient group, including Glasgow Coma
Score (GCS) on admission, were similar to those from
1984 to 2002. CSF laboratory findings on admission did
not differ between the two groups (Table 2).
The administered antibiotics were similar in the two
study periods, as the recommended empiric therapeutic
regimen given on suspicion of bacterial meningitis has
not changed in Germany. In the recent study period, 52
Table 1 Epidemiological data on admission
2003–2015 1984–2002 P value
Age (median (minimum, maximum)) 62 (20, 78) 51 (14, 87) 0.012
Gender (male/female) 19/36 46/41 0.039
GCS (median (minimum, maximum)) 12 (3, 15) 10 (3, 15) 0.224
Fever on admission 74.1 % 96.6 % 0.0001
Neck stiffness 84.9 % 95.4 % 0.057
Chronic underlying disease 40 % 29.9 % 0.275
ENT focus 67.3 % 57.5 % 0.290
CSF fistula 5.5 % 20.7 % 0.015
Direct admission 65.5 % 59.8 % 0.5950
GCS Glasgow Coma Score, ENT ear nose and throat, CSF cerebrospinal fluid
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out of the 55 patients were treated with ceftriaxone
(dosage 4 g intravenously per day). Three patients were
treated with meropenem and vancomycin because the
medical history of these patients prompted physicians to
initially expect a broader range of possible causative bac-
teria (two patients with CSF fistula and one patient with
an eroding carcinoma of the ethmoid). There were 37
patients also treated initially with ampicillin, in case of
listeria. Seven patients also received acyclovir to treat for
the possibility of Herpes simplex virus (HSV) type 1 in-
fection. As soon as S. pneumoniae was identified as the
causative pathogen, the antibiotic regimen was adopted,
resulting in monotherapy with ceftriaxone. Patients re-
ceived additional antibiotic therapy only when additional
infectious sites were identified (such as aspiration pneu-
monia). All pneumococcal isolates were highly suscep-
tible to third-generation cephalosporins with a minimal
inhibitory concentration (MIC) <0.5 μg/ml. The same
was true for all isolates identified from patients in the
previous study periods. This high rate of cephalosporine
susceptibility is in accordance with nationwide surveil-
lance data indicating more than 99 % susceptibility of
pneumococci to third-generation cephalosporines [13].
The median time from arrival at the hospital to adminis-
tration of antibiotics was 38 minutes (minimum 5 mi-
nutes, maximum 240 minutes) for all patients who were
directly admitted to our hospital.
The percentage of patients treated with dexametha-
sone significantly increased to 85.5 % in 2003–2015
from 18.4 % in 1984–2002 (p < 0.001). This was the
consequence of the results of the European dexa-
methasone trial that were published in 2002 [7]. For
both study periods together, mortality was signifi-
cantly lower in the group of patients who received
steroids vs. in the group of patients who did not re-
ceive steroids (9 % vs. 30 %, p = 0.036). A lack of cor-
ticosteroid therapy was associated with death in all
patients in both study periods (OR = 14.26 (1.58–
128.72), p = 0.018) but not with an unfavorable
outcome in multivariate analysis. There was no asso-
ciation between corticosteroid treatment and outcome
when both study periods were evaluated separately;
this can most likely be explained by the fact that the
distribution of steroids was quite homogenous in both
periods (rate of steroid use 85.5 % in 2003–2015 and
18.4 % in 1984–2002).
Thirty-six patients received dexamethasone at a dos-
age of 4 × 10 mg intravenously per day for 4 days. Four
patients received a dosage of 3 × 8 mg. Three patients
received hydrocortisone instead of dexamethasone for
treatment of sepsis. We were only able to obtain data on
the timing of dexamethasone therapy for patients who
were directly admitted to our hospital. In these patients,
the median time from arrival at the hospital to adminis-
tration of steroids was 45 minutes (minimum 5 minutes,
maximum 420 minutes). None of the patients received
dexamethasone before the first administration of
antibiotics.
The most common cause of pneumococcal meningitis
identified in our study was sinusitis and/or mastoiditis.
This was found in as many as 36 of 55 patients (65 %).
Among patients who were transferred from another hos-
pital, 80 % had ENT-focused disease. Among patients
who were directly admitted to our hospital through our
emergency department, 43 % had ENT-focused disease.
Surgery was conducted within 24 hours of hospital
Fig. 1 Duration of symptoms before hospital admission. Duration of
symptoms in study period 1 and study period 2 until hospital
admission; *p < 0.05
Table 2 Laboratory findings on admission
2003–2015 1984–2002 P value
Cells in CSF/μl (mean ± SD) 3411 ± 4457 3936 ± 5699 0.671
Protein in CSF in mg/dl
(mean ± SD)
582 ± 851.1 458.3 ± 391.4 0.393
Glucose in CSF in mg/dl
(mean ± SD)
27.33 ± 37.61 22.32 ± 23.31 0.430
CSF cerebrospinal fluid, SD standard deviation















Fig. 2 Outcome of patients with pneumococcal meningitis.
Mortality (Glasgow Outcome Scale (GOS) = 1) was reduced in
patients with pneumococcal meningitis in the current study period
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admission in all patients with ENT-focused disease. Two
patients with endocarditis underwent cardiac surgery.
Of 55 patients, 54 were treated at the NICU with a
median stay in the NICU of 8 days (minimum 1 day,
maximum 62 days). There were intracranial complica-
tions in 52.7 % of patients (Table 3). The most frequent
complication was the development of brain edema
(14.5 %), followed by epileptic seizures (14.5 %), cerebral
ischemia (12.7 %), and hydrocephalus (10.9 %). Overall,
the rate of intracranial complications was lower in the
current study period than from 1984 to 2002 (p = 0.01).
In addition to the intracranial complications assessed in
the former study period, 22 patients (40 %) had vascu-
lopathy detected by transcranial ultrasound (defined as
systolic cerebral blood flow >150 cm/sec in any intracra-
nial artery).
There was a significant reduction in disseminated
intravasal coagulopathy: every other systemic complica-
tion occurred at an unchanged frequency in both study
periods. Six patients developed tetraparesis due to crit-
ical illness polyneuropathy.
Per standardized protocol at the ICU, all patients with
impaired consciousness were positioned with a head up
tilt of 30°, in case of an increase in intracranial pressure.
Impaired consciousness was associated with hydroceph-
alus in six patients, five of whom received an external
ventricular drain and deep sedation. Deep sedation in
combination with continuous drainage of the CSF was
sufficient to keep the intracranial pressure below
20 mmHg in all patients. Intubation was required in 28
patients for airway protection and/or respiratory insuffi-
ciency. Patients were normoventilated with an arterial
partial pressure of carbon dioxide (paCO2) of 32–
36 mmHg. The need for intubation was associated with a
GOS <5 at the time of discharge from our hospital (p =
0.003). The systolic blood pressure was kept above
100 mmHg. There were 58 % of patients requiring vaso-
pressors. The mortality rate and the rate of unfavorable out-
comes was not statistically different in patients who
required or did not require vasopressors (p = 0.241).
Patients were treated with nimodipine if increased
cerebral blood flow was detected by transcranial ultra-
sound (which is routinely performed in patients with
meningitis every other day during the hospital stay).
Whenever nimodipine was administered, patients re-
ceived an arterial line for continuous blood pressure sur-
veillance and their arterial blood pressure was kept at
120 mmHg or higher. Antiepileptic treatment was
started in patients with epileptic seizures. The following
drugs were used: phenytoin (n = 4 patients), levetirace-
tam (n = 2 patients), valproic acid (n = 1 patient) and
carbamazepine (n = 1 patient). Treatment was successful,
as there were no further seizures in any of these
patients.
Overall, only 3 out of 55 patients (5.5 %) died: In a 74-
year-old female patient who was suffering from a
progressive eroding carcinoma of the ethmoid and who
did not improve after 9 days of intensive care, therapy was
withdrawn in accordance with the patient’s provision and
in agreement with the relatives. A 74-year-old man died
only 1 day after admission with massive cerebritis. Fur-
thermore, a 66-year-old woman died after 14 days of ther-
apy due to multiple systemic complications (sepsis with
disseminated intravasal coagulopathy, acute coronary syn-
drome and acute renal failure). Compared to 1984–2002,
mortality was significantly lower in 2003–2015 (24.1 % vs.
5.5 %, p < 0.05).
Follow-up lumbar puncture (LP) was performed in 35
patients (64 %); of these, 9 patients received a repeat LP
at our ICU within the first 2 days to confirm a diagnosis
made at a different hospital. In those patients, CSF re-
sults had improved (decrease in pleocytosis and protein
and increase in CSF/serum glucose ratio) or did not dif-
fer significantly from the first LP. In the remaining 25
patients, LP was repeated later (median 10 days, mini-
mum 3 days, maximum 25 days), and inflammatory pa-
rameters were found to be reduced in 23 of the 25
patients.
Causative pathogens could not be isolated in any of
the CSF samples obtained during repeat LP (gram stain,
culture, antigen test, PCR). CSF pleocytosis had in-
creased in only two patients: in one patient CSF pleocy-
tosis increased from 500 cells/μl to 1909 cells/μl. As a
switch was observed from granulocytic to lymphocytic
pleocytosis and cultures remained sterile, the antibiotic
regimen (consisting of ceftriaxone 4 g/day intravenously)
Table 3 Complications in the course of the disease
2003–2015 1984–2002 P value
Intracranial complicationsa 52.7 % 74.7 % 0.010
Brain edema 14.5 % 28.7 % 0.066
Epileptic seizures 14.5 % 27.6 % 0.098
Cerebral ischemia 12.7 % 18.4 % 0.485
Hydrocepahlus 10.9 %b 16.1 % 0.464
Sinus thrombosis 7.3 % 9.1 % 0.766
Intracranial bleeding 3.6 % 9.1 % 0.316
Cerebral vasculopthy 40 % not assessed
Hearing loss 32.7 % 19.5 % 0.23
Systemic complications 34.5 % 48.3 % 0.12
Pneumonia 21.8 % 21.8 % 1.0
Sepsis 16.4 % 31.0 % 0.074
Renal failure 5.5 % 11.5 % 0.371
Disseminated intravasal coagulation 3.6 % 23 % 0.002
aNot including cerebral vasculopathy, as this was not assessed in the previous
study period. See main text for details. bFive of six patients required an
external ventricular drain
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was not changed. The patient improved (92 cells/μl, pro-
tein 136 cells/μl, CSF glucose 82 mg/μl on follow-up LP
10 days later). Another patient had persistent pleocytosis
with persistently decreased CSF/serum glucose ratios for
one month, without detection of a causative pathogen.
As a consequence, he received a second ENT operation
on the sphenoidal and ethmoidal sinuses, which were
identified as a possible second persisting focus in
addition to the initial mastoiditis for which his first oper-
ation was performed. There was improvement in the
CSF parameters on subsequent follow-up LPs.
Notably, all survivors in the current patient group
were discharged with a GOS of 3 or more and, thus, the
reduction of mortality was not associated with an in-
crease in patients with a GOS of 2. The rate of discharge
of patients with a GOS of 5 was similar in the two study
periods (Fig. 2).
A low GCS on admission and chronic underlying dis-
eases (defined as malignancies not in remission, diabetes
mellitus, abuse of alcohol, terminal renal failure, chronic
hepatitis or immunosuppressive therapy) were associated
with an unfavorable outcome (Table 4). On multivariate
analysis, a low GCS (GCS <10) on admission was also
associated with an unfavorable outcome (GOS <5) in
both study periods together (OR = 3.47 (1.23–9.24), p =
0.13) and from 1984–2002 (OR = 3.97 (1.18–13.37), p =
0.026). Interestingly, this was no longer the case for the
study period 2003–2015 (OR = 2.32 (0.45–11.95), p =
0.316).
As in the historical patient group, the GOS in pa-
tients with intracranial complications was still worse
than in those who did not develop intracranial
complications (p = 0.011). This also held true in a
multivariate analysis where intracranial complications
were associated with unfavorable outcome (all patients in
both study periods, OR = 11.5 (3.2–41.33, p < 0.001; study
period 2003–2015, OR = 6.44 (1.21–34.22, p = 0.029)).
Patients who developed a manifest ischemic stroke were
discharged with a lower GOS than those who did not suf-
fer from cerebral ischemia (p = 0.010). Nevertheless, the
current outcome did not differ among patients who devel-
oped vasculopathy (p = 0.107), seizures (p = 0.089), brain
oedema (p = 0.198) or hydrocephalus (0.598) in compari-
son to those who did not develop these complications
(Table 5). This is different to the earlier study period
where the development of any of these complications was
associated with a low GOS (Fig. 3). Also, on multivariate
analysis there was association between systemic complica-
tions and an unfavorable outcome altogether (OR = 3.57
(1.39–9.14), p = 0.043) and in both study periods (1984–
2002, OR = 3.48 (1.04–11.63), 2003–2015, OR = 6.29
(1.21–32.79), p = 0.029). High serum C-reactive protein
(CRP) was associated with an adverse outcome (not
assessed in the former study period).
Discussion
The most striking finding in the study period from 2003
to 2015 is the low mortality rate of 5.5 %, representing a
marked difference to the results in our earlier study
from 1984 to 2002, in which 24.1 % of patients died.
This result is striking: although the overall development
in Europe is that case fatality rates have generally de-
creased in the past 20 years, such a drastic improvement
has not been reported before. While 30 % of patients
Table 4 Conditions that are associated with unfavorable outcome
GOS 5 GOS <5 OR (95 % CI) P value 2003–2015
Gender (male/female) 7/16 12/20 1.37 (0.43–4.29) 0.775
Age (median ± SD) 60 ± 16.3 63 ± 12.6 0.152
Direct admission to tertiary center 56.5 % 18.8 % 0.18 (0.05–0.59) 0.005
Sinusitis 56.5 % 71.9 % 1.97 (0.63–6.07) 0.2644
Chronic underlying disease 21.7 % 53.1 % 4.08 (1.21–13.70) 0.026
Fever on admission 78.3 % 68.8 % 0.68 (0.20–2.40) 0.755
Neck stiffness on admission 91.3 % 75.0 % 0.38 (0.063–2.10) 0.442
Symptoms of meningitis before admission in days (median ± SD) 1 ± 2.65 1 ± 1.13 - 0.734
GCS on admission (median; minimum, maximum) 12; 3, 15 10; 3, 15 - 0.006
FND on admission 39.1 % 18.8 % 0.36 (0.11–1.22) 0.128
Leucocytes in serum (G/l) on admission (mean ± SD) 17.8 ± 7.74 18.67 ± 8.45 - 0.718
CRP on admission (mean ± SD) 14.73 ± 9.42 23.83 ± 11.54 - 0.007
Leucocytes in CSF/μl on admission (mean ± SD) 3623 ± 3898 3237 ± 4934 - 0.460
Protein in CSF in mg/dl on admission (mean ± SD) 432 ± 417 697 ± 107 - 0.094
Glucose in CSF in mg/dl on admission (mean ± SD) 48 ± 46 10 ± 16 - <0.001
SD standard deviation, GCS Glasgow Coma Score, FND focal neurologic deficit, CRP C-reactive protein, CSF cerebrospinal fluid
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with pneumococcal meningitis in a prospective study in
the Netherlands from 1998–2002 died, a nationwide
study from the Netherlands that included more than
1400 patients admitted between 2006 and 2014 reported
mortality of 18 % [1, 2]. In a study from Sweden the
mortality rate was 11 % in patients suffering from
pneumococcal meningitis [14]. One important reason
for the improvement of outcome in this serious disease
is the administration of adjunctive dexamethasone,
which has been introduced in central Europe as the
standard of care after the European Dexamethasone
Study from the Netherlands in 2002 and the results of
several meta-analyses [7, 15].
In the current analysis, intracranial complications oc-
curred significantly less frequently than in the former
study period (p < 0.01). The same trend was seen for sys-
temic complications. Thus, the reduction in intracranial
complications and, potentially, also in systemic compli-
cations might have contributed to the reduction in mor-
tality. Improved outcome in patients with pneumococcal
meningitis given dexamethasone has only been associ-
ated with reduced mortality due to systemic reasons,
and not with reduction in intracranial complications
[16]. It is impossible to draw causal pathophysiologic
conclusions from clinical associations, but reduction in
Table 5 Factors associated with an adverse outcome in the
course of the disease
GOS 5 GOS < 5 OR (95 % CI) P value
2015
Intracranial complications
Cerebral ischemia 4.3 % 18.8 % 5.08 (0.57–45.47) 0.219
Seizures 8.7 % 18.8 % 2.423 (0.44–13.28) 0.446
Intracranial
hemorrhage
0 % 6.3 % 3.85a (0.178–84.19) 0.504
Intracranial venous
thrombosis
4.3 % 9.4 % 2.27 (0.22–23.41) 0.632
Brain edema 8.7 % 18.8 % 2.42 (0.44–13.28) 0.446
Hydrocephalus 8.7 % 18.8 % 2.42 (0.44–13.28) 0.446
Systemic complications
DICa 4.3 % 3.1 % 0.71 (0.04–11.98) 1.0
Sepsis 4.3 % 25.0 % 7.33 (0.85–63.49) 0.064
Pneumonia 8.7 % 31.3 % 4.77 (0.93–24.41) 0.055
Renal failure 0 % 9.4 % 5.58b (0.27–113.50) 0.257
aThese patients had thrombocytopenia, decreased antithrombin-III and clinical
signs of bleeding (at sites of injections or mucous membranes). bOR was
calculated adding 0.5 to each value. DIC disseminated intravasal coagulation, GOS
Glasgow Outcome Scale
Fig. 3 Outcome in patients with intracranial complications. For details see text. GOS Glasgow Outcome Scale
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intracranial complications due to dexamethasone treat-
ment is well in line with pathophysiological concepts of
pneumococcal meningitis. As multiple animal studies
have shown, subarachnoid inflammation triggered by
bacterial compounds and danger signals is a major driver
of intracranial complications, and dexamethasone ther-
apy can lower the degree of inflammation in pneumo-
coccal meningitis [17].
It seems difficult to attribute the very low mortality
rate of 5.5 % to the introduction of adjunctive dexa-
methasone only. Thus, we first checked for other differ-
ences in our two populations that might have had an
additional impact on mortality. One factor that might
have contributed to the improvement in outcome in the
recent study population could be the shorter duration of
symptoms before presentation to an emergency depart-
ment, as an early start of antibiotic therapy is known to
contribute to a better prognosis in acute bacterial men-
ingitis [18]. This has only been shown for the delay of
antibiotics from the time point of arrival of the patient
at the hospital but should also be a factor for the time
period of disease duration until the patient is admitted
to the emergency department.
Other differences in the study populations are less
likely to be of relevance: the current patients were older,
which is an unlikely factor for reduced mortality, as
increased age has been reported to be an independent
risk factor for death due to bacterial meningitis [19].
Second, the proportion of female patients was higher in
the current study, but female gender has also been
described as a risk factor for adverse outcome in the
elderly with meningitis. The fact that fewer patients
suffered from a CSF fistula as an underlying condition
with pneumococcal meningitis is not to our knowledge
known to be a risk factor for good or adverse outcome.
In addition to antibiotic therapy being started earlier
and the administration of dexamethasone, treatment
options in intensive care medicine have improved and
might have contributed to the outcome. With knowledge
on complications in pneumococcal meningitis there is
an increasing chance to anticipate and detect these com-
plications, which enables physicians to take adequate
measures early. Unfortunately, most ICU interventions
in pneumococcal meningitis have not been evaluated in
prospective studies. Examples are interventions to
decrease increased cranial pressure when suspected, in-
cluding deep sedation, head tilt elevation at 30° and
placement of an external ventricular drain in the case of
clinically relevant hydrocephalus. In line with these data,
a recent study from Sweden showed that patients with
acute bacterial meningitis seem to benefit from medical
care at an ICU experienced in the treatment of patients
with severe neurological diseases and the possibility to
undertake adequate measures (e.g., placement of an
external ventricular drain) [20]. It is of great importance
that hyperventilation of such patients is avoided as it
lowers the intracranial pressure at the cost of reduced
cerebral blood flow.
Further interventions in our patients included treatment
with nimodipine and the prevention of a drop in cerebral
perfusion pressure when vasculopathy has been identified
by transcranial ultrasound [11, 21]. In sinus thrombosis,
intravenous heparin was used (whenever the transverse
sinus was not affected). Such measures have potentially
dangerous side effects, especially in severely ill patients
who are sedated and in whom neuromonitoring is limited.
Nevertheless, the low mortality in this study and the data
from Glimaker et al. [20] suggest that patients with
pneumococcal meningitis benefit from treatment at cen-
ters specialized in the treatment of patients with severe
neurologic diseases and we consider it likely that mortality
rates at other single specialized centers in central Europe
are also lower than in nationwide studies. In addition, it is
a common practice at our center to perform early surgery
in the case of a suspected focus of pneumococcal menin-
gitis (e.g., sinusitis and/or mastoiditis). In recent years we
have managed to surgically clear the focus of infection
within 24 h in these patients. Although not evaluated in
any prospective studies, we consider this as a crucial fac-
tor for outcome as it is in line with the generally accepted
premise “ubi pus, ibi evacua”. However, it is completely
unclear whether this has a positive effect on outcome and,
to our knowledge, is not done in all centers. Therefore,
clinical studies should be undertaken to address this topic.
Our study has several limitations. The data were col-
lected retrospectively. Thus, interesting factors that
might have contributed to the improved outcome could
not be satisfactorily identified and, thus, were not evalu-
ated. For example, the time to the initiation of antibiotic
therapy in hospital is known to be crucial in bacterial
meningitis [14, 18, 22] and it is possible that antibiotics
were administered earlier in recent years than in the
study period from 1984 to 2002.
In the course of the disease, especially at the intensive
care unit, physicians and nurses are well-trained to
optimize patient care continuously. This includes careful
titration of sedation, keeping blood pressure in prede-
fined corridors, sustain optimal mechanical ventilation,
detect arising complications even before they become
clinically relevant and counteract them immediately.
The impact of such interventions is extremely difficult
to measure, and it is impossible to assess them in a
retrospective study. Furthermore, we did not assess
long-term outcome: 58 % of patients were transferred to
rehabilitation units and hopefully further improved. This
is very likely, as a relatively large proportion of patients
(25 %) were sent there with a GOS of 4 and none of the
patients were discharged with a GOS of 2. Thus, the
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chances are high that the long-term unfavorable out-
come in this study was even lower than reported.
Finally, vaccination against S. pneumoniae has been
recommended with PCV-7 in 2006 and PCV-13 in 2009
for children in Germany. This has resulted in a decline
in vaccine serotypes as the causative pneumococcal iso-
lates from adults with pneumococcal meningitis (and an
increase in serotype 23B) [23]. Unfortunately, informa-
tion on serotyping of the isolates is not available in our
retrospective dataset. Thus, we cannot comment on
whether this change of serotype distribution might have
had an impact on outcome in our patient population.
Conclusions
In this study, the current mortality in patients with
pneumococcal meningitis was 5.5 %, which is signifi-
cantly lower than in an earlier study from 1984 to 2002
and the lowest reported mortality for this disease in
Europe so far. In addition to the introduction of cortico-
steroids as routine adjunctive therapy, many other inter-
ventions performed in the ICU probably contributed to
the improved outcome. As the impact of single interven-
tions remains unclear, this study points at the necessity
for a prospective evaluation of ICU interventions in
pneumococcal meningitis.
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